Results 211 to 220 of about 7,022,792 (370)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

FRI0320 CN-1A AUTOANTIBODIES ARE SPECIFIC FOR SPORADIC INCLUSION BODY MYOSITIS [PDF]

open access: bronze, 2019
Louise Pyndt Diederichsen   +8 more
openalex   +1 more source

Inclusion bodies enriched for p62 and polyubiquitinated proteins in macrophages protect against atherosclerosis

open access: yesScience Signaling, 2016
Ismail Sergin   +8 more
semanticscholar   +1 more source

Inclusion Bodies

open access: yesBiomedical and Pharmacology Journal, 2016
N. Balachander   +3 more
openaire   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy